To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
242 Newest Publications about the topic cancer genes
rss
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
01-01-2013 | Wanjuan Yang; Jorge Soares; Patricia Greninger; Elena J. Edelman; Howard Lightfoot; Simon Forbes; Nidhi Bindal; Dave ..., Nucleic Acids Research, 2013
Alterations in cancer genomes strongly influence clinical responses to treatment and in many instances are potent biomarkers for response to drugs. The Genomics of Drug Sensitivity in Cancer (GDSC) database (www.cancerRxgene.org) is the largest public resource for information on drug ...
Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
01-12-2012 | Hanna M. Leinonen; Anna-Kaisa Ruotsalainen; Ann-Marie Määttä; Heidi M. Laitinen; Suvi M. Kuosmanen; Emilia Kansanen; ..., Cancer Research, 2012
Nuclear factor erythroid-2 related factor 2 (Nrf2) is a transcription factor that regulates protection against a wide variety of toxic insults to cells, including cytotoxic cancer chemotherapeutic drugs. Many lung cancer cells harbor a mutation in either Nrf2 or its inhibitor Keap1 resulting ...
Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy
23-11-2012 | N Kanagawa, T Yanagawa, T Nakagawa, N Okada, S Nakagawa, Cancer Gene Therapy, 2012
Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy Cancer Gene Therapy advance online publication, November 23 2012. doi:10.1038/cgt.2012.85 Authors: N Kanagawa, T Yanagawa, T Nakagawa, N Okada & S ...
Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-|[alpha]| leads to synergistic antitumor activity
16-11-2012 | Z Yuan, G Syrkin, A Adem, R Geha, J Pastoriza, C Vrikshajanani, T Smith, T J Quinn, G Alemu, H Cho, C J Barrett, W A ..., Cancer Gene Therapy, 2012
Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity Cancer Gene Therapy advance online publication, November 16 2012. doi:10.1038/cgt.2012.83 Authors: Z Yuan, G Syrkin, A ...
Comparative analysis of somatic copy-number alterations across different human cancer types reveals two distinct classes of breakpoint hotspots
15-11-2012 | Yudong Li; Li Zhang; Robyn L. Ball; Xinle Liang; Jianrong Li; Zhenguo Lin; Han Liang, Human Molecular Genetics, 2012
Somatic copy-number alterations (SCNAs) play a crucial role in the development of human cancer. However, it is not well understood what evolutionary mechanisms contribute to the global patterns of SCNAs in cancer genomes. Taking advantage of data recently available through The Cancer Genome ...
Efficient non‐viral gene therapy with FasL and Del1 fragments in mice
08-11-2012 | Hisataka Kitano, Atsushi Mamiya, Shinichiro Kokubun, Chiaki Hidai, The Journal of Gene Medicine, 2012
Abstract Background Expression of FasL in cancer cells is currently being explored as a potential cancer therapy. Because high levels of FasL are necessary for effective treatment, current methods typically rely on use of highly efficient viral vectors. However, because viral ...
[News & Analysis] Genetics: Cancer Gene Data Casts Doubt on Popular Research Method
06-11-2012 | Eliot Marshall, Science , 2012
Researchers argue that most work on Myc, a gene linked to aggressive cancers, needs to be reevaluated. They say that Myc's cancerous effects are actually much broader, and that a flawed experimental method may have thrown off previousresearch.
Functional impact bias reveals cancer drivers
01-11-2012 | Abel Gonzalez-Perez; Nuria Lopez-Bigas, Nucleic Acids Research, 2012
Identifying cancer driver genes and pathways among all somatic mutations detected in a cohort of tumors is a key challenge in cancer genomics. Traditionally, this is done by prioritizing genes according to the recurrence of alterations that they bear. However, this approach has some known ...
Discovering the hidden sub-network component in a ranked list of genes or proteins derived from genomic experiments
01-11-2012 | Luz García-Alonso; Roberto Alonso; Enrique Vidal; Alicia Amadoz; Alejandro de María; Pablo Minguez; Ignacio Medina; ..., Nucleic Acids Research, 2012
Genomic experiments (e.g. differential gene expression, single-nucleotide polymorphism association) typically produce ranked list of genes. We present a simple but powerful approach which uses protein–protein interaction data to detect sub-networks within such ranked lists of genes or ...
The transcriptional landscape and mutational profile of lung adenocarcinoma [RESEARCH]
01-11-2012 | Jeong-Sun Seo; Young Seok Ju; Won-Chul Lee; Jong-Yeon Shin; June Koo Lee; Thomas Bleazard; Junho Lee; Yoo Jin Jung; ..., Genome Research, 2012
All cancers harbor molecular alterations in their genomes. The transcriptional consequences of these somatic mutations have not yet been comprehensively explored in lung cancer. Here we present the first large scale RNA sequencing study of lung adenocarcinoma, demonstrating its power to ...
Netmeeting
